Immunotherapy Drugs Market Size, Share & Trends by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029
Immunotherapy drugs are designed to enhance the immune response or modulate the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cellsThe immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, reflecting a compound annual growth rate (CAGR) of 15.3%. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies. However, the market faces challenges such as the complexities involved in developing antibody therapeutics.
The Antibody drugs segment maintains major market share in the forecast period.
Based on type, the immunotherapy drugs market is divided into antibody drugs, inhibitor drugs, interferons & interleukins, cancer vaccines, and other immunotherapy drugs, which include oncolytic virus therapy and t-cell therapy. Antibody drugs hold the major market share. Increasing cancer incidence, the growing adoption of biological therapies, heightened investment in R&D, and supportive government policies are anticipated to propel market growth.
The Cancer segment is anticipated to dominate Immunotherapy Drugs Market through 2023-2029.
Based on applications, the immunotherapy drugs market is divided into cancer, autoimmune & inflammatory diseases, hematology, osteology, neurology, and other applications, including ophthalmology, dermatology, and cardiovascular diseases. Cancer commanded the largest market share in 2023. Elevated cancer rates, increased adoption of biological therapies, substantial R&D investment, and favorable government policies are expected to drive market growth during the forecast period. Companies in the immunotherapy drugs sector are exemplifying innovation through the development of new therapies, strategic collaborations, and enhanced spending on clinical research to explore immunotherapy treatments for cancer. These efforts aim to boost the immune system's capability to fight cancer, offering new hope and improved patient outcomes.
The Intravenous Route segment is anticipated to grow at the fastest pace throughout the forecast period.
Based on the route of administration, the immunotherapy drugs market is broadly segmented into intravenous, subcutaneous, and other routes of administration (intravitreal and intramuscular). In 2023, the intravenous route of administration segment accounted for the largest share of the immunotherapy drugs market. This segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate are attributed to the growing preference for intravenous routes owing to its direct delivery into the bloodstream, ensuring rapid and consistent therapeutic effects for several conditions, including cancer and autoimmune diseases.
Hospitals segment generated the highest revenue in 2024 in the market.
Based on end users, the immunotherapy drugs market is broadly segmented into hospitals, long-term care facilities, and other end users (specialty care centers). In 2023, the hospitals segment commanded the largest share of the immunotherapy drugs market. Hospitals extensively use mAbs for their targeted therapy, rapid diagnostic applications, and efficacy in treating several disease indications, including cancer, autoimmune disorders, and infectious diseases.
The North America accounted for the largest share in the immunotherapy drugs market.
In 2023, North America accounted for the largest share of the global immunotherapy drugs market. The growth in the North American market can be attributed to rising immunotherapy research, the expansion of the healthcare sector, growing cancer prevalence, and the increasing approval and adoption of immunotherapy drugs for treating cancer and other chronic diseases. North America has witnessed significant growth in medical research advancements, growing clinical trials, and the developing biopharmaceutical industry. With increased research-driven activities and a high prevalence of cancer and chronic diseases, the demand for immunotherapies in North America is expected to rise significantly.
Breakdown of supply-side primary interviews by company type, designation, and region:
This report studies the Immunotherapy Drugs market based on type, application, route of administration, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total Immunotherapy Drugs market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
The Antibody drugs segment maintains major market share in the forecast period.
Based on type, the immunotherapy drugs market is divided into antibody drugs, inhibitor drugs, interferons & interleukins, cancer vaccines, and other immunotherapy drugs, which include oncolytic virus therapy and t-cell therapy. Antibody drugs hold the major market share. Increasing cancer incidence, the growing adoption of biological therapies, heightened investment in R&D, and supportive government policies are anticipated to propel market growth.
The Cancer segment is anticipated to dominate Immunotherapy Drugs Market through 2023-2029.
Based on applications, the immunotherapy drugs market is divided into cancer, autoimmune & inflammatory diseases, hematology, osteology, neurology, and other applications, including ophthalmology, dermatology, and cardiovascular diseases. Cancer commanded the largest market share in 2023. Elevated cancer rates, increased adoption of biological therapies, substantial R&D investment, and favorable government policies are expected to drive market growth during the forecast period. Companies in the immunotherapy drugs sector are exemplifying innovation through the development of new therapies, strategic collaborations, and enhanced spending on clinical research to explore immunotherapy treatments for cancer. These efforts aim to boost the immune system's capability to fight cancer, offering new hope and improved patient outcomes.
The Intravenous Route segment is anticipated to grow at the fastest pace throughout the forecast period.
Based on the route of administration, the immunotherapy drugs market is broadly segmented into intravenous, subcutaneous, and other routes of administration (intravitreal and intramuscular). In 2023, the intravenous route of administration segment accounted for the largest share of the immunotherapy drugs market. This segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate are attributed to the growing preference for intravenous routes owing to its direct delivery into the bloodstream, ensuring rapid and consistent therapeutic effects for several conditions, including cancer and autoimmune diseases.
Hospitals segment generated the highest revenue in 2024 in the market.
Based on end users, the immunotherapy drugs market is broadly segmented into hospitals, long-term care facilities, and other end users (specialty care centers). In 2023, the hospitals segment commanded the largest share of the immunotherapy drugs market. Hospitals extensively use mAbs for their targeted therapy, rapid diagnostic applications, and efficacy in treating several disease indications, including cancer, autoimmune disorders, and infectious diseases.
The North America accounted for the largest share in the immunotherapy drugs market.
In 2023, North America accounted for the largest share of the global immunotherapy drugs market. The growth in the North American market can be attributed to rising immunotherapy research, the expansion of the healthcare sector, growing cancer prevalence, and the increasing approval and adoption of immunotherapy drugs for treating cancer and other chronic diseases. North America has witnessed significant growth in medical research advancements, growing clinical trials, and the developing biopharmaceutical industry. With increased research-driven activities and a high prevalence of cancer and chronic diseases, the demand for immunotherapies in North America is expected to rise significantly.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Respondent: Supply Side (70%), Demand side (30%)
- By Designation: C-level (55%), Director-level (20%), and Others (25%)
- By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)
- Merck & Co., Inc. (US)
- Johnson & Johnson Services, Inc. (US)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Pfizer Inc. (US)
- AstraZeneca (UK)
- Novartis AG (Switzerland)
- Amgen Inc. (US)
- Gilead Sciences, Inc. (UK)
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Teva Pharmaceutical Industries Ltd (Israel)
- GSK PLC (US)
- Abbvie Inc. (US)
This report studies the Immunotherapy Drugs market based on type, application, route of administration, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total Immunotherapy Drugs market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Market Drivers: The key factors driving the overall market growth are technological advancements in antibody engineering, Increased demand for antibody therapies in clinical cancer treatment, and Growing demand for personalized medicines and targeted therapies
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the Immunotherapy Drugs market.
- Market Penetration: Comprehensive information on Immunotherapy Drugs offered by the top 15 players in the market. The report analyzes the Immunotherapy Drugs market by Type, Application, Route of Administration, End User and Region
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of Immunotherapy Drugs across key geographic regions.
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Immunotherapy Drugs market
- Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Immunotherapy Drugs market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.5 UNITS CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT OF ECONOMIC RECESSION ON IMMUNOTHERAPY DRUGS MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW
4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE AND COUNTRY (2023)
4.3 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,
2024 VS. 2029 (USD BILLION)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Technological advancements in antibody engineering
5.2.1.2 Increasing demand for antibody therapeutics in clinical cancer treatment
5.2.1.3 Growing demand for personalized medicines and targeted therapies
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory approval process for immunotherapy drugs
5.2.2.2 High cost of monoclonal antibody therapeutics
5.2.3 OPPORTUNITIES
5.2.3.1 Rising number of approvals for CAR T-cell therapies
5.2.3.2 Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutes
5.2.4 CHALLENGES
5.2.4.1 Complexities in development of antibody therapeutics
5.3 PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 KEY STAKEHOLDERS & BUYING CRITERIA
5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.4.2 KEY BUYING CRITERIA
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 PRICING ANALYSIS
5.7.1 AVERAGE SELLING PRICE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER
5.7.2 AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER, 2021–2023
5.7.3 INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION
5.7.4 INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION
5.8 ECOSYSTEM ANALYSIS
5.8.1 ROLE IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
5.9 PATENT ANALYSIS
5.10 TECHNOLOGY ANALYSIS
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Gene editing
5.10.1.2 High-throughput screening
5.10.1.3 Next-generation sequencing
5.10.2 COMPLEMENTARY TECHNOLOGIES
5.10.2.1 Nanotechnology
5.10.2.2 Artificial intelligence
5.11 INVESTMENT & FUNDING SCENARIO
5.11.1 MAJOR INVESTMENTS AND FUNDING
5.11.2 OTHER INVESTMENTS AND FUNDING
5.12 KEY CONFERENCES & EVENTS, 2024–2025
5.13 CASE STUDY ANALYSIS
5.13.1 CASE STUDY 1: EFFICACY OF KEYTRUDA IN CANCER TREATMENT
5.13.2 CASE STUDY 2: EFFECTIVE USE OF LYNPARZA IN PROSTATE CANCER TREATMENT
5.13.3 CASE STUDY 3: CLINICAL TRIALS OF ORPATHYS (SAVOLITINIB)
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY ANALYSIS
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.2.1 Germany
5.14.1.2.2 UK
5.14.1.2.3 Rest of Europe
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 South Korea
5.14.1.3.4 Australia
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.1 North America
5.14.2.2 Europe
5.14.2.3 Asia Pacific
5.14.2.4 Latin America
5.14.2.5 Middle East & Africa
6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE
6.1 INTRODUCTION
6.2 ANTIBODY DRUGS
6.2.1 ROBUST CLINICAL PIPELINE OF ANTIBODY THERAPEUTICS TO SUPPORT MARKET GROWTH
6.3 INHIBITOR DRUGS
6.3.1 INCREASED FOCUS ON DEVELOPMENT OF TARGET MEDICINES AND COMBINATION THERAPIES TO FUEL MARKET GROWTH
6.4 INTERFERONS & INTERLEUKINS
6.4.1 INCREASED FOCUS ON R&D AND DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO AUGMENT MARKET GROWTH
6.5 CANCER VACCINES
6.5.1 RISING FOCUS ON RESEARCH ACTIVITIES AND CLINICAL TRIALS TO SPUR MARKET GROWTH
6.6 OTHER IMMUNOTHERAPY DRUGS
7 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 CANCER
7.2.1 LARGE R&D SPENDING AND HIGH GOVERNMENT INVESTMENTS TO DRIVE MARKET
7.3 AUTOIMMUNE & INFLAMMATORY DISEASES
7.3.1 ADVANCEMENTS IN MOLECULAR ENGINEERING AND INTRODUCTION OF BIOLOGICAL DRUGS TO PROPEL MARKET GROWTH
7.4 HEMATOLOGY
7.4.1 INCREASED R&D IN CELL-BASED THERAPIES, MONOCLONAL ANTIBODIES, AND IMMUNE CHECKPOINT INHIBITORS TO AID MARKET GROWTH
7.5 OSTEOLOGY
7.5.1 GROWING INCIDENCE OF OSTEOPOROSIS-RELATED FRACTURES TO DRIVE MARKET
7.6 NEUROLOGY
7.6.1 ADVANCEMENTS IN NEUROLOGICAL DRUG DEVELOPMENT TO BOOST MARKET GROWTH
7.7 OTHER APPLICATIONS
8 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 INTRAVENOUS ROUTE OF ADMINISTRATION
8.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE TO PROPEL MARKET GROWTH
8.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION
8.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO AID MARKET GROWTH
8.4 OTHER ROUTES OF ADMINISTRATION
9 IMMUNOTHERAPY DRUGS MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS
9.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH
9.3 LONG-TERM CARE FACILITIES
9.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
9.4 OTHER END USERS
10 IMMUNOTHERAPY DRUGS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 US to dominate North American immunotherapy drugs market during forecast period
10.2.3 CANADA
10.2.3.1 Rising government initiatives for research on regenerative medicine to drive market
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing investments in healthcare research to fuel market growth
10.3.3 UK
10.3.3.1 Favorable government initiatives and high R&D investments to propel market growth
10.3.4 FRANCE
10.3.4.1 Increasing adoption of immunotherapy drugs and growing focus on healthcare R&D to augment market growth
10.3.5 ITALY
10.3.5.1 Strong focus on clinical research and stringent government regulations to propel market growth
10.3.6 SPAIN
10.3.6.1 Favorable government initiatives to spur market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Less-stringent regulatory framework and high incidence of cancer to drive market
10.4.3 JAPAN
10.4.3.1 Rising geriatric population and increasing government support to augment market growth
10.4.4 INDIA
10.4.4.1 Increasing prevalence of cancer and rising government healthcare investments to aid market growth
10.4.5 SOUTH KOREA
10.4.5.1 Strong biopharmaceutical sector and favorable government initiatives to support market growth
10.4.6 AUSTRALIA
10.4.6.1 High prevalence of cancer and increased expenditure on health services to propel market growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Developed healthcare infrastructure and unified public health system to fuel market growth
10.5.3 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MIDDLE EAST: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 Saudi Arabia
10.6.2.1.1 Increasing focus on R&D and growing government support to spur market growth
10.6.2.2 UAE
10.6.2.2.1 Technological advancements and increased government focus on healthcare to support market growth
10.6.2.3 Rest of GCC Countries
10.6.3 REST OF MIDDLE EAST
10.7 AFRICA
10.7.1 INCREASING HEALTHCARE FUNDING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Type footprint
11.5.5.3 Application footprint
11.5.5.4 Route of administration footprint
11.5.5.5 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT APPROVALS
11.9.2 DEALS
11.9.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 MERCK & CO., INC.
12.1.1.1 Business overview
12.1.1.2 Products/Services/Solutions offered
12.1.1.3 Recent developments
12.1.1.3.1 Product approvals
12.1.1.3.2 Deals
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 JOHNSON & JOHNSON SERVICES, INC.
12.1.2.1 Business overview
12.1.2.2 Products/Services/Solutions offered
12.1.2.3 Recent developments
12.1.2.3.1 Product approvals
12.1.2.3.2 Deals
12.1.2.3.3 Expansions
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 F. HOFFMANN-LA ROCHE LTD.
12.1.3.1 Business overview
12.1.3.2 Products/Services/Solutions offered
12.1.3.3 Recent developments
12.1.3.3.1 Product approvals
12.1.3.3.2 Deals
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 ASTRAZENECA
12.1.4.1 Business overview
12.1.4.2 Products/Services/Solutions offered
12.1.4.3 Recent developments
12.1.4.3.1 Product approvals
12.1.4.3.2 Deals
12.1.4.3.3 Expansions
12.1.5 PFIZER INC.
12.1.5.1 Business overview
12.1.5.2 Products/Services/Solutions offered
12.1.5.3 Recent developments
12.1.5.3.1 Product approvals
12.1.5.3.2 Deals
12.1.6 AMGEN INC.
12.1.6.1 Business overview
12.1.6.2 Products/Services/Solutions offered
12.1.6.3 Recent developments
12.1.6.3.1 Product approvals
12.1.6.3.2 Expansions
12.1.7 NOVARTIS AG
12.1.7.1 Business overview
12.1.7.2 Products/Services/Solutions offered
12.1.7.3 Recent developments
12.1.7.3.1 Product approvals
12.1.7.3.2 Deals
12.1.8 ELI LILLY AND COMPANY
12.1.8.1 Business overview
12.1.8.2 Products/Services/Solutions offered
12.1.8.3 Recent developments
12.1.8.3.1 Product approvals
12.1.8.3.2 Deals
12.1.9 SANOFI
12.1.9.1 Business overview
12.1.9.2 Products/Services/Solutions offered
12.1.9.3 Recent developments
12.1.9.3.1 Product approvals
12.1.9.3.2 Deals
12.1.10 BRISTOL-MYERS SQUIBB COMPANY
12.1.10.1 Business overview
12.1.10.2 Products/Services/Solutions offered
12.1.10.3 Recent developments
12.1.10.3.1 Product approvals
12.1.10.3.2 Deals
12.1.11 GILEAD SCIENCES, INC.
12.1.11.1 Business overview
12.1.11.2 Products/Services/Solutions offered
12.1.11.3 Recent developments
12.1.11.3.1 Product approvals
12.1.11.3.2 Deals
12.1.11.3.3 Other developments
12.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED
12.1.12.1 Business overview
12.1.12.2 Products/Services/Solutions offered
12.1.12.3 Recent developments
12.1.12.3.1 Product approvals
12.1.12.3.2 Deals
12.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.1.13.1 Business overview
12.1.13.2 Products/Services/Solutions offered
12.1.13.3 Recent developments
12.1.13.3.1 Deals
12.1.14 ABBVIE INC.
12.1.14.1 Business overview
12.1.14.2 Products/Services/Solutions offered
12.1.14.3 Recent developments
12.1.14.3.1 Product approvals
12.1.14.3.2 Deals
12.1.15 GSK PLC
12.1.15.1 Business overview
12.1.15.2 Products/Services/Solutions offered
12.1.15.3 Recent developments
12.1.15.3.1 Product approvals
12.1.15.3.2 Deals
12.1.15.3.3 Other developments
12.2 OTHER PLAYERS
12.2.1 IMMUNOCORE HOLDINGS PLC
12.2.2 ASTELLAS PHARMA INC.
12.2.3 GENMAB A/S
12.2.4 MACROGENICS, INC.
12.2.5 FERRING BV
12.2.6 Y-MABS THERAPEUTICS, INC.
12.2.7 BIOGEN
12.2.8 KYOWA KIRIN CO., LTD.
12.2.9 SWEDISH ORPHAN BIOVITRUM AB
12.2.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.5 UNITS CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT OF ECONOMIC RECESSION ON IMMUNOTHERAPY DRUGS MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW
4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE AND COUNTRY (2023)
4.3 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,
2024 VS. 2029 (USD BILLION)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Technological advancements in antibody engineering
5.2.1.2 Increasing demand for antibody therapeutics in clinical cancer treatment
5.2.1.3 Growing demand for personalized medicines and targeted therapies
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory approval process for immunotherapy drugs
5.2.2.2 High cost of monoclonal antibody therapeutics
5.2.3 OPPORTUNITIES
5.2.3.1 Rising number of approvals for CAR T-cell therapies
5.2.3.2 Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutes
5.2.4 CHALLENGES
5.2.4.1 Complexities in development of antibody therapeutics
5.3 PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 KEY STAKEHOLDERS & BUYING CRITERIA
5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.4.2 KEY BUYING CRITERIA
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 PRICING ANALYSIS
5.7.1 AVERAGE SELLING PRICE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER
5.7.2 AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER, 2021–2023
5.7.3 INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION
5.7.4 INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION
5.8 ECOSYSTEM ANALYSIS
5.8.1 ROLE IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
5.9 PATENT ANALYSIS
5.10 TECHNOLOGY ANALYSIS
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Gene editing
5.10.1.2 High-throughput screening
5.10.1.3 Next-generation sequencing
5.10.2 COMPLEMENTARY TECHNOLOGIES
5.10.2.1 Nanotechnology
5.10.2.2 Artificial intelligence
5.11 INVESTMENT & FUNDING SCENARIO
5.11.1 MAJOR INVESTMENTS AND FUNDING
5.11.2 OTHER INVESTMENTS AND FUNDING
5.12 KEY CONFERENCES & EVENTS, 2024–2025
5.13 CASE STUDY ANALYSIS
5.13.1 CASE STUDY 1: EFFICACY OF KEYTRUDA IN CANCER TREATMENT
5.13.2 CASE STUDY 2: EFFECTIVE USE OF LYNPARZA IN PROSTATE CANCER TREATMENT
5.13.3 CASE STUDY 3: CLINICAL TRIALS OF ORPATHYS (SAVOLITINIB)
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY ANALYSIS
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.2.1 Germany
5.14.1.2.2 UK
5.14.1.2.3 Rest of Europe
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 South Korea
5.14.1.3.4 Australia
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.1 North America
5.14.2.2 Europe
5.14.2.3 Asia Pacific
5.14.2.4 Latin America
5.14.2.5 Middle East & Africa
6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE
6.1 INTRODUCTION
6.2 ANTIBODY DRUGS
6.2.1 ROBUST CLINICAL PIPELINE OF ANTIBODY THERAPEUTICS TO SUPPORT MARKET GROWTH
6.3 INHIBITOR DRUGS
6.3.1 INCREASED FOCUS ON DEVELOPMENT OF TARGET MEDICINES AND COMBINATION THERAPIES TO FUEL MARKET GROWTH
6.4 INTERFERONS & INTERLEUKINS
6.4.1 INCREASED FOCUS ON R&D AND DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO AUGMENT MARKET GROWTH
6.5 CANCER VACCINES
6.5.1 RISING FOCUS ON RESEARCH ACTIVITIES AND CLINICAL TRIALS TO SPUR MARKET GROWTH
6.6 OTHER IMMUNOTHERAPY DRUGS
7 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 CANCER
7.2.1 LARGE R&D SPENDING AND HIGH GOVERNMENT INVESTMENTS TO DRIVE MARKET
7.3 AUTOIMMUNE & INFLAMMATORY DISEASES
7.3.1 ADVANCEMENTS IN MOLECULAR ENGINEERING AND INTRODUCTION OF BIOLOGICAL DRUGS TO PROPEL MARKET GROWTH
7.4 HEMATOLOGY
7.4.1 INCREASED R&D IN CELL-BASED THERAPIES, MONOCLONAL ANTIBODIES, AND IMMUNE CHECKPOINT INHIBITORS TO AID MARKET GROWTH
7.5 OSTEOLOGY
7.5.1 GROWING INCIDENCE OF OSTEOPOROSIS-RELATED FRACTURES TO DRIVE MARKET
7.6 NEUROLOGY
7.6.1 ADVANCEMENTS IN NEUROLOGICAL DRUG DEVELOPMENT TO BOOST MARKET GROWTH
7.7 OTHER APPLICATIONS
8 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 INTRAVENOUS ROUTE OF ADMINISTRATION
8.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE TO PROPEL MARKET GROWTH
8.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION
8.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO AID MARKET GROWTH
8.4 OTHER ROUTES OF ADMINISTRATION
9 IMMUNOTHERAPY DRUGS MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS
9.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH
9.3 LONG-TERM CARE FACILITIES
9.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
9.4 OTHER END USERS
10 IMMUNOTHERAPY DRUGS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 US to dominate North American immunotherapy drugs market during forecast period
10.2.3 CANADA
10.2.3.1 Rising government initiatives for research on regenerative medicine to drive market
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing investments in healthcare research to fuel market growth
10.3.3 UK
10.3.3.1 Favorable government initiatives and high R&D investments to propel market growth
10.3.4 FRANCE
10.3.4.1 Increasing adoption of immunotherapy drugs and growing focus on healthcare R&D to augment market growth
10.3.5 ITALY
10.3.5.1 Strong focus on clinical research and stringent government regulations to propel market growth
10.3.6 SPAIN
10.3.6.1 Favorable government initiatives to spur market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Less-stringent regulatory framework and high incidence of cancer to drive market
10.4.3 JAPAN
10.4.3.1 Rising geriatric population and increasing government support to augment market growth
10.4.4 INDIA
10.4.4.1 Increasing prevalence of cancer and rising government healthcare investments to aid market growth
10.4.5 SOUTH KOREA
10.4.5.1 Strong biopharmaceutical sector and favorable government initiatives to support market growth
10.4.6 AUSTRALIA
10.4.6.1 High prevalence of cancer and increased expenditure on health services to propel market growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Developed healthcare infrastructure and unified public health system to fuel market growth
10.5.3 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MIDDLE EAST: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 Saudi Arabia
10.6.2.1.1 Increasing focus on R&D and growing government support to spur market growth
10.6.2.2 UAE
10.6.2.2.1 Technological advancements and increased government focus on healthcare to support market growth
10.6.2.3 Rest of GCC Countries
10.6.3 REST OF MIDDLE EAST
10.7 AFRICA
10.7.1 INCREASING HEALTHCARE FUNDING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Type footprint
11.5.5.3 Application footprint
11.5.5.4 Route of administration footprint
11.5.5.5 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT APPROVALS
11.9.2 DEALS
11.9.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 MERCK & CO., INC.
12.1.1.1 Business overview
12.1.1.2 Products/Services/Solutions offered
12.1.1.3 Recent developments
12.1.1.3.1 Product approvals
12.1.1.3.2 Deals
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 JOHNSON & JOHNSON SERVICES, INC.
12.1.2.1 Business overview
12.1.2.2 Products/Services/Solutions offered
12.1.2.3 Recent developments
12.1.2.3.1 Product approvals
12.1.2.3.2 Deals
12.1.2.3.3 Expansions
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 F. HOFFMANN-LA ROCHE LTD.
12.1.3.1 Business overview
12.1.3.2 Products/Services/Solutions offered
12.1.3.3 Recent developments
12.1.3.3.1 Product approvals
12.1.3.3.2 Deals
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 ASTRAZENECA
12.1.4.1 Business overview
12.1.4.2 Products/Services/Solutions offered
12.1.4.3 Recent developments
12.1.4.3.1 Product approvals
12.1.4.3.2 Deals
12.1.4.3.3 Expansions
12.1.5 PFIZER INC.
12.1.5.1 Business overview
12.1.5.2 Products/Services/Solutions offered
12.1.5.3 Recent developments
12.1.5.3.1 Product approvals
12.1.5.3.2 Deals
12.1.6 AMGEN INC.
12.1.6.1 Business overview
12.1.6.2 Products/Services/Solutions offered
12.1.6.3 Recent developments
12.1.6.3.1 Product approvals
12.1.6.3.2 Expansions
12.1.7 NOVARTIS AG
12.1.7.1 Business overview
12.1.7.2 Products/Services/Solutions offered
12.1.7.3 Recent developments
12.1.7.3.1 Product approvals
12.1.7.3.2 Deals
12.1.8 ELI LILLY AND COMPANY
12.1.8.1 Business overview
12.1.8.2 Products/Services/Solutions offered
12.1.8.3 Recent developments
12.1.8.3.1 Product approvals
12.1.8.3.2 Deals
12.1.9 SANOFI
12.1.9.1 Business overview
12.1.9.2 Products/Services/Solutions offered
12.1.9.3 Recent developments
12.1.9.3.1 Product approvals
12.1.9.3.2 Deals
12.1.10 BRISTOL-MYERS SQUIBB COMPANY
12.1.10.1 Business overview
12.1.10.2 Products/Services/Solutions offered
12.1.10.3 Recent developments
12.1.10.3.1 Product approvals
12.1.10.3.2 Deals
12.1.11 GILEAD SCIENCES, INC.
12.1.11.1 Business overview
12.1.11.2 Products/Services/Solutions offered
12.1.11.3 Recent developments
12.1.11.3.1 Product approvals
12.1.11.3.2 Deals
12.1.11.3.3 Other developments
12.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED
12.1.12.1 Business overview
12.1.12.2 Products/Services/Solutions offered
12.1.12.3 Recent developments
12.1.12.3.1 Product approvals
12.1.12.3.2 Deals
12.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.1.13.1 Business overview
12.1.13.2 Products/Services/Solutions offered
12.1.13.3 Recent developments
12.1.13.3.1 Deals
12.1.14 ABBVIE INC.
12.1.14.1 Business overview
12.1.14.2 Products/Services/Solutions offered
12.1.14.3 Recent developments
12.1.14.3.1 Product approvals
12.1.14.3.2 Deals
12.1.15 GSK PLC
12.1.15.1 Business overview
12.1.15.2 Products/Services/Solutions offered
12.1.15.3 Recent developments
12.1.15.3.1 Product approvals
12.1.15.3.2 Deals
12.1.15.3.3 Other developments
12.2 OTHER PLAYERS
12.2.1 IMMUNOCORE HOLDINGS PLC
12.2.2 ASTELLAS PHARMA INC.
12.2.3 GENMAB A/S
12.2.4 MACROGENICS, INC.
12.2.5 FERRING BV
12.2.6 Y-MABS THERAPEUTICS, INC.
12.2.7 BIOGEN
12.2.8 KYOWA KIRIN CO., LTD.
12.2.9 SWEDISH ORPHAN BIOVITRUM AB
12.2.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
